Consequential Amendment to the Fees in Respect of Drugs and Medical Devices Order

From Health Canada

Current status: Open

Opened on March 06, 2021 and will close to new input on March 21, 2021.

A change is proposed to the definition of "new active substance" in the Fees in Respect of Drugs and Medical Devices Order to match a proposed definition change in the Food and Drug Regulations for "innovative drug" that was previously consulted on under the Regulations Amending the Food and Drug Regulations (Improving Access to Generics). Stakeholders are invited to comment on the amended definition for "new active substance".

Join in: how to participate

Send us an email

Send an email to hc.cro-brc.sc@canada.ca with your ideas or comments to make yourself heard.

Who is the focus of this consultation

We will engage with:

Goal of the consultation

To receive feedback on concerns or impacts of the consequential amendment to align the term "new active substance" in the Fees Order with the proposed definition of "innovative drug" in the Improving Access to Generics Regulations.

Key questions for discussion

Your ideas and inputs are sought on amending the definition of "new active substance" in the Fees Order to aligned with the proposed definition of "innovative drug" pursuant to the Access to Generics Regulations.

Related information

Contact us

Cost Recovery Office
Resource Management and Operations Directorate
Health Products and Food Branch
Health Canada
250 Lanark Avenue, Graham Spry Building
Ottawa, ON K1A 0K9
A.L. 2004B

Telephone: 613-957-6690
Email: hc.cro-brc.sc@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: